Impact of sleeve gastrectomy on the periodontal status of patients with and without type 2 diabetes: a 1-year prospective real-world study

被引:1
|
作者
Bi, Xiaocheng [1 ,2 ,3 ,4 ]
Zhao, Peikai [5 ,6 ]
Liu, Teng [5 ,7 ]
Zhu, Tao [5 ,6 ]
Li, Yuxuan [5 ,6 ]
Xiong, Sisi [5 ,6 ]
Liu, Shaozhuang [5 ,7 ]
Hu, Xiaole [8 ]
Huang, Xin [5 ,7 ]
机构
[1] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Periodontol, Jinan, Shandong, Peoples R China
[2] Shandong Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China
[3] Shandong Engn Res Ctr Dent Mat & Oral Tissue Regen, Jinan, Shandong, Peoples R China
[4] Shandong Prov Clin Res Ctr Oral Dis, Jinan, Shandong, Peoples R China
[5] Shandong Univ, Dept Gen Surg, Div Bariatr & Metab Surg, Qilu Hosp, Jinan, Shandong, Peoples R China
[6] Shandong Univ Tradit Chinese Med, Clin Coll 1, Jinan, Shandong, Peoples R China
[7] Shandong Univ, State Key Univ Lab Diabet & Obes Surg, Jinan, Shandong, Peoples R China
[8] Shandong Univ, Dept Operating Room, Qilu Hosp, Jinan, Shandong, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
基金
中国国家自然科学基金;
关键词
type; 2; diabetes; periodontitis; obesity; sleeve gastrectomy; prospective studies; BARIATRIC SURGERY; TNF-ALPHA; OBESITY; MELLITUS; DISEASES; HEALTH; IL-6;
D O I
10.3389/fendo.2024.1431728
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Periodontitis is a chronic inflammatory disease potentially associated with obesity and type 2 diabetes (T2D). Sleeve gastrectomy (SG) has shown substantial effect on weight loss and treatment of T2D. However, there is no direct evidence comparing the impact of SG on the periodontal status of patients with and without T2D. Objectives: To determine the impact of SG on the periodontal status of patients with and without T2D in a real-world setting. Methods: In a prospective and two-armed cohort design, participants who were scheduled for SG at an affiliated hospital between April 2022 and December 2022 were approached for eligibility. After a clinical evaluation and oral examination, those with periodontitis were included and further divided into the DM group (diabetic) and the Control group (non-diabetic) with a 1-year follow-up after surgery. The primary outcome was the periodontal status of patients at 12 months after SG. The secondary outcomes included weight loss, diabetes remission, and alterations in inflammatory markers for up to 1 year after SG. Results: Fifty-seven and 49 patients were included in the DM and the Control group, respectively. Before surgery, patients in the DM group had further worsened periodontal condition compared with those in the Control group. Accompanied by weight loss and glucose reduction, patients in both groups demonstrated significant decreases in plaque index (PLI) and bleeding index (BI) with no alterations in probing depth or clinical attachment loss for up to 1 year after SG. Even patients in the DM group achieved less TWL% (32.79 +/- 6.20% vs. 37.95 +/- 8.34, P<0.01), their periodontal condition had more substantial improvement with no significant difference in PLI and BI between groups at 1 year after SG. We also observed a significant reduction in the levels of high sensitive C-reactive protein and interleukin-6 in both groups at 1 year after SG. Conclusion: Both patients with and without T2D demonstrated improved periodontal status for up to 1 year after SG. Patients with T2D achieved less weight loss but a more substantial improvement in periodontal condition. The significant reduction in inflammatory biomarkers contributed to the improvement of periodontal status after SG.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Weight Loss, Type 2 Diabetes, and Nutrition in 355 Patients with Obesity Undergoing Sleeve Gastrectomy with Transit Bipartition: Two-Year Outcomes
    Al, Muzaffer
    Taskin, Halit Eren
    OBESITY FACTS, 2022, 15 (05) : 717 - 729
  • [32] Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes
    Pinto, Maria
    Brennan, Lillian
    Diehl, Katie
    Lin, Shally
    Heacock, Samantha
    JOURNAL OF PHARMACY TECHNOLOGY, 2025, 41 (01) : 22 - 31
  • [33] Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan
    Katsuyama, Hisayuki
    Hakoshima, Mariko
    Heshiki, Takahiro
    Iida, Sakura
    Adachi, Hiroki
    Yanai, Hidekatsu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 213
  • [34] Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study
    Wang, Jun-Wei
    Jin, Chun-Hua
    Ke, Jiang-Feng
    Ma, Yi-Lin
    Wang, Yu-Jie
    Lu, Jun-Xi
    Li, Mei-Fang
    Li, Lian-Xi
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [35] Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients
    Silva-Nunes, Jose
    Nascimento, Edite
    Louro, Joana
    Dores, Jorge
    Laginha, Teresa
    Goncalves-Ferreira, Ana
    Alves, Marta
    Souto, Selma B.
    Cunha, Nelson
    Pina, Elsa
    Duarte, Rui
    Raposo, Joao Filipe
    METABOLITES, 2022, 12 (11)
  • [36] Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real-world prospective cohort study
    Zucchini, Stefano
    Ripoli, Carlo
    Cherubini, Valentino
    Coccioli, Maria Susanna
    Delvecchio, Maurizio
    De Marco, Rosaria
    Franceschi, Roberto
    Gallo, Francesco
    Graziani, Vanna
    Iafusco, Dario
    Innaurato, Stefania
    Lasagni, Anna
    Lombardo, Fortunato
    Marigliano, Marco
    Monti, Sara
    Pascarella, Filomena
    Pezzino, Giulia
    Predieri, Barbara
    Rabbone, Ivana
    Schiaffini, Riccardo
    Trada, Michela
    Tumini, Stefano
    Scaramuzza, Andrea
    DIABETES OBESITY & METABOLISM, 2024, 26 (02) : 754 - 757
  • [37] Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study
    van Houtum, William
    Schrombges, Patrick
    Amadid, Hanan
    van Bon, Arianne C.
    Braae, Uffe C.
    Hoogstraten, Charlotte
    Herrings, Hans
    DIABETES THERAPY, 2024, 15 (08) : 1749 - 1768
  • [38] Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study
    Kick, Anastas
    M'Rabet-Bensalah, Khadija
    Acquistapace, Flavio
    Amadid, Hanan
    Ambuhl, Robert A.
    Braae, Uffe Christian
    Item, Flurin
    Schultes, Bernd
    Zuger, Thomas
    Rudofsky, Gottfried
    DIABETES THERAPY, 2024, 15 (03) : 623 - 637
  • [39] PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan
    Suzuki, Ryo
    Amadid, Hanan
    Major-Pedersen, Atheline
    Yabe, Daisuke
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (08) : 1047 - 1056
  • [40] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Garcia-Perez, Luis-Emilio
    Boye, Kristina S.
    Rosilio, Myriam
    Jung, Heike
    Heitmann, Elke
    Norrbacka, Kirsi
    Federici, Marco Orsini
    Gentilella, Raffaella
    Guerci, Bruno
    Giorgino, Francesco
    Aigner, Ulrich
    Sapin, Helene
    DIABETES THERAPY, 2021, 12 (07) : 1929 - 1946